Página 75 - Dimensiones éticas de las regulaciones en salud

74
5. Giles J. Warning flag for ethics boards. Nature 2006; 443: 127.
6. Angell M. Is Academic Medicine for Sale? N Engl J Med 2000; 342: 1516.
7. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest Authorship and
Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry
Documents From Rofecoxib Litigation. JAMA 2008; 299: 1800-1812.
8. American Association of Medical Colleges. Protecting Patients, Preserving
Integrity, Advancing Health: Accelerating the Implementation of COI Policies
in Human Subjects Research. Website. Available athttp://www.aamc.org/
research/coi/start.htm
9. Campbell EG, Weissman JS, Vogeli C, Clarridge BR, Abraham M, Marder
JE, Koski G. Financial Relationships between Institutional Review Board
Members and Industry. N Engl J Med 2006; 355: 2321-2329.
10. Levinsky NG. Nonfinancial Conflicts of Interest in Research. N Engl J Med
2002; 347: 759.
11. Couzin J. Breakdown of the Year: Scientific Fraud. Science 2006; 314:
1853.
12. Kennedy D. Responding to Fraud. Science 2006; 314: 1353.
13. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B,
Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ.
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen
in Patients with Rheumatoid Arthritis. N Engl J Med 2000; 343: 1520-
1528.
14. Chan AW, Hróbjartsson H, Haahr MT, Gøtzsche PC, Altman DG.
Empirical Evidence for Selective Reporting of Outcomes in Randomized
Trials: Comparison of Protocols to Published Articles. JAMA 2004; 291:
2457-2465.
15. Martinson B, Anderson M, De Vrie R. Scientists behaving badly. Nature
2005; 435: 737-738.
16. Sox H, Rennie D. Research Misconduct, Retraction, and Cleansing the
Medical Literature: Lessons from the Poehlman Case. Annals of Internal
Medicine 2006; 144: 609-613.
17. Odling-Smee L, Giles J, Fuyuno I, Cyranoski D, Marris E. Misconduct
Special Where are they now? Nature 2007; 445: 244-245.